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Factors predisposing to individual susceptibility to contact allergic dermatitis are ill defined. This study was
designed to characterize the response of allergic and tolerant individuals’ T-lymphocytes after exposure to
p-phenylenediamine (PPD). Peripheral blood mononuclear cells (PBMCs) from allergic patients proliferated
when treated with PPD and Bandrowski’s base (BB) and secreted IL-1a, -1b, -4, -5, -6, -8, -10, and -13; IFN-g; tumor
necrosis factor-a; MIP-1a/b; MCP-1 (monocyte chemotactic protein-1); and RANTES. PBMCs from tolerant
individuals were stimulated to proliferate only with BB, and they secreted significantly lower levels of Th2
cytokines. Principal component analysis showed that genes are differentially expressed between the patient
groups. A network-based analysis of microarray data showed upregulation of T helper type 2 (Th2) gene
pathways, including IL-9, in allergic patients, but a regulatory gene profile in tolerant individuals. Real-time PCR
confirmed the observed increase in Th2 cytokine gene transcription in allergic patients. Purified CD4þ and
CD8þ T cells from allergic patients were stimulated to proliferate and secrete Th2 cytokines following antigen
exposure. Only CD4þ T cells from tolerant individuals were stimulated by BB, and levels of Th2 cytokines were
80% lower. The nature of the antigenic determinant stimulating PBMCs and levels of Th2 cytokines, including
IL-9, was confirmed in a validation cohort. These studies show increased activity of Th2 cytokines in CD4þ and
CD8þ T cells from individuals with allergic contact dermatitis.
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INTRODUCTION
Allergic contact dermatitis is a delayed-type, cell-mediated
immune reaction, occurring after cutaneous exposure to
certain low-molecular-weight chemicals. Classic studies by
Landsteiner and Jacobs (1935) showed that irreversible
protein modulation is a prerequisite for immune activation,
a hypothesis that is still widely accepted today. Cutaneous
dendritic cells capture hapten-modified protein and, after
acquiring additional T helper type 1 (Th1) or Th2 polarizing
signals (Cumberbatch et al., 2005; Mori et al., 2008), migrate
toward draining lymph nodes to present peptides to naive
T cells. Subsequent exposure to the same chemical is
associated with the cutaneous migration of antigen-specific
CD4þ and CD8þ T cells, the destruction of keratinocytes,
and the development of contact dermatitis (Kehren et al.,
1999; Akiba et al., 2002). Our understanding of the cellular
basis of allergic contact dermatitis derives to a large extent
from murine models in which CD8þ T cells are effectors,
mediating cytotoxicity through FAS- and perforin-dependent
pathways (Kehren et al., 1999; Akiba et al., 2002;
Saint-Mezard et al., 2004, 2005; Vocanson et al., 2006). In
contrast, CD4þ T cells are thought to play a more regulatory
role, possibly inhibiting pathogenic responses and the
development of contact dermatitis.
In humans, our understanding of the involvement of
different T-cell populations in the development of contact
dermatitis is less well defined. The contact allergen 2,4-
dinitrochlorobenzene stimulates IFN-g secretion from both
blood-derived CD4þ and CD8þ T cells (Pickard et al.,
2007) and punch biopsies from delayed-type hypersensitivity
reactions (Lecart et al., 2001) in all exposed individuals.
Lecart et al. (2001) also isolated IL-5- and/or IL-10-secreting
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T-cell clones and postulated that they may regulate the size of
the induced immune response. Similarly, the metal allergen
nickel, which complexes with the major histocompatibility
complex and specific T-cell receptors (Gamerdinger et al.,
2003; Lu et al., 2003; Moulon et al., 2003), stimulates IFN-g
secretion from CD4þ and CD8þ T cells isolated from
allergic individuals (Cavani et al., 2000), whereas, in
contrast, tolerant individuals’ T cells seem to prevent the
development of contact dermatitis through multiple regula-
tory pathways (Cavani et al., 1998, 2003).
Recently, we have used the hair dye component
p-phenylenediamine (PPD) as a model allergen with which
to explore the chemical and cellular bases of contact
dermatitis. PPD, a diamine-substituted aromatic ring, is
susceptible to sequential oxido-conjugation reactions in
aqueous solution and in contact with skin. The ultimate
product of these reactions is the trimer Bandrowski’s base
(BB) (Picardo et al., 1990). T cells from PPD-allergic and
-tolerant individuals (Sieben et al., 2002; Coulter et al.,
2008), but not cord blood (Coulter et al., 2008), were
stimulated to proliferate by BB, implying an acquired immune
response that is not translated into an allergic reaction. This
hypothesis is supported by the low incidence of patch
test–positive reactions to BB in PPD-allergic patients (White
et al., 2006). Eilstein et al. (2006, 2008) demonstrated that
primary quinonediimine intermediates bind to nucleophilic
amino acids via a complex series of reaction mechanisms,
and, indeed, protein modified with PPD quinonediimine may
be an important antigenic determinant (Coulter et al., 2008).
In this respect, lymphocytes from allergic patients alone were
found to be specifically stimulated with PPD.
In contrast to 2,4-dinitrochlorobenzene and nickel (dis-
cussed above), in a murine model of PPD-induced contact
sensitization Th2 cytokines, IgE antibodies, and mast cells
were found to play a crucial role in the development of tissue
pathology (Yokozeki et al., 2003). T-cell clones from allergic
human patients secrete predominantly Th2 cytokines (IL-4,
-5, and -13) following PPD stimulation (Sieben et al., 2002;
Coulter et al., 2008), which is in accordance with the recently
described increased expression of IL-4, IL-13, and IL-31 genes
in allergic dermatitis (Neis et al., 2006).
The aim of this study was to explore the response of
allergic and tolerant individuals’ peripheral blood mono-
nuclear cells (PBMCs) and purified CD4þ and CD8þ T cells
after PPD and BB exposure. PBMCs and CD4þ and CD8þ
T cells from allergic patients were stimulated to proliferate
and secrete cytokines, including IL-5 and -13, after treatment
with PPD and BB. Tolerant individuals’ PBMCs and CD4þ ,
but not CD8þ , T cells were also specifically stimulated (but
only with BB); however, only low levels of the Th2 cytokines
IL-5 and IL-13 were detected. A microarray study established
that it was possible to differentiate allergic and tolerant
patient samples on the basis of differing gene expression
profiles. Furthermore, a network-based analysis of the data
identified Th2 and regulatory cytokine signaling pathways in
allergic and tolerant individuals, respectively. These data,
which were validated in an expanded independent cohort,
support the hypothesis that PPD-mediated Th2 cytokine
secretion from T cells contributes to the development of
contact allergic dermatitis.
RESULTS
Peripheral blood mononuclear cell proliferation with
PPD and BB
Peripheral blood mononuclear cells from allergic patients
were stimulated to proliferate by both PPD and BB (n¼ 5;
maximum stimulation index (SI) PPD: 39.0±25.5; BB:
45.1±36.9). PBMCs from tolerant individuals were not
specifically stimulated with PPD (SI less than 2); however,
BB treatment was associated with a concentration-dependent
proliferative response (n¼ 6; SI 10.4±7.4; Table 1).
Cytokine and chemokine secretion from PPD- and
BB-stimulated PBMCs
Significant concentrations (more than 30 pg/ml) of IL-1a,
IL-1b, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IFN-g, TNF-a (tumor
necrosis factor-a), MCP-1, MIP-1a, MIP-1b, IP-10, and
RANTES were detected from allergic patients’ PBMCs
stimulated with PPD or BB (Table 2). BB stimulation of
tolerant patients’ PBMCs was associated with similar levels of
IL-1a, IL-1b, IFN-g IL-6, IL-8, IL-10, IP-10, MIP-1b, MCP-1,
TNF-a, and RANTES secretion (Table 2; P40.05). Allergic
and tolerant patients’ PBMCs differed in terms of the extent of
IL-4, IL-5, IL-13, and MIP-1a secreted (Figure 1). Levels of
IL-4 and IL-5 found in supernatants from tolerant samples
stimulated with BB were below the limit of detection,
whereas the level of IL-13 secretion was approximately
15% of that found in equivalent samples from allergic
patients. BB-stimulated cells from tolerant individuals
secreted high levels of IL-8 and IL-10; however, when cells
from allergic patients and tolerant individuals were com-
pared, the values did not reach statistical significance
(Table 2). Tolerant patients’ PBMCs stimulated with PPD
secreted only IL-8 and MCP-1.
Principal component analysis of the gene expression data
deriving from PPD- and BB-stimulated PBMCs
To identify in more detail the global differences between
allergic and tolerant individuals, principal component
analysis was applied randomly to the microarray data, with
no preformed opinions. From the two components showing
greatest variance (18.71 and 12.49%, respectively), it was
possible to draw a clear division and separate the data points
from allergic and tolerant individuals, irrespective of antigen
treatment (Figure 2a).
Allergic and tolerant patient gene expression profiles and
biologically related ontologies
Lists showing gene expression altered as a result of PBMC
stimulation with PPD and BB for 24hours indicated that
allergic patients’ cells expressed genes related to positive
regulation of cell proliferation, apoptosis, inflammatory response,
humoral immune response, and lymphocyte activation. Toler-
ant individuals’ samples stimulated with BB underwent similar
biological processes, with the following exceptions: (1) antigen
stimulation was associated with negative regulation of cell
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proliferation and (2) genes relating to the humoral immune
response were not regulated. PPD stimulation of tolerant
patients’ PBMCs was not associated with biological processes
relating to an immune response (Figure 2b).
Individual genes of interest showing an increased expres-
sion after antigen stimulation of allergic and tolerant patients’
PBMCs are listed in Figure 3. Increased expression of the Th2
cytokines (IL-5, IL-9, and IL-13) and chemokines (CCL17 and
Table 2. Cytokine and chemokine secretion from PPD- and BB-stimulated lymphocytes
Cytokine/chemokine (pg/ml)1
Patients Antigen IL-1a IL-1b IL-4 IL-5 IL-6 IL-8 IL-10 IL-13
Allergic (n=5) PPD 167.42 138.7 109.5 117 19.5 97.0 50.9 1342.1
BB 222.0 108.5 112.9 120 1,196 97.0 148.3 1,697.6
Tolerant (n=6) PPD 0 0.1 0.6 1.1 10.5 429.6 0 18.2
BB 248.6 57.4 4.9 17.4 1,120.5 361.4 230.9 252.6
Cytokine/chemokine (pg/ml)
Patients Antigen IFN-c IP-10 MCP-1 MIP-1a MIP-1b RANTES TNF-a
Allergic (n=5) PPD 36.3 85.7 111.9 96.5 451.0 515.0 60.9
BB 138.8 74.9 290.5 1,009.1 540.2 694.5 189.0
Tolerant (n=6) PPD 6.1 30.4 352.6 0 0 0 3.2
BB 38.5 169.1 281.9 128.9 540.2 635.2 108.1
BB, Bandrowski’s base; PPD, p-phenylenediamine; TNF-a, tumor necrosis factor-a.
1Levels of the cytokines and chemokines TGF-a, IL-12, IL-15, IL-17, and eotaxin in PPD- or BB-treated samples were not significantly different from those in
solvent-treated controls.
2Data represent average cytokine data from allergic patients and tolerant individuals with vehicle control levels (without antigen; less than 10pg/ml
cytokine, with the exception of IL-13 (50 pg/ml) and IL-6 and IL-8 (up to 1 ng/ml)) subtracted.
Table 1. Concentration-dependent proliferation of lymphocytes from allergic and tolerant individuals
Lymphocyte proliferation (SI)
PPD (lM) BB (lM)
TT 0.1 0.5 1 2 5 10 0.1 0.5 1 2 5 10
Allergic patients
11 84.9 36.3 52.0 9.2 1.1 0.5 0.3 72.0 111.5 88.1 77.1 20.2 0.5
2 41.9 34.9 55.5 55.1 49.1 32.5 0.3 26.0 37.1 48.0 48.0 66.1 11.3
3 18.9 4.7 6.4 8.6 2.0 0.1 0.2 10.9 14.7 13.6 14.7 3.9 1.7
4 87.8 12.5 34.4 42.2 54.2 74.1 37.9 12.7 13.0 20.4 19.7 5.1 1.5
5 58.0 8.4 15.1 5.5 4.1 6.8 1.0 6.4 19.5 25.0 29.5 7.1 0.4
Tolerant patients
1 25.8 o2 o2 o2 o2 o2 o2 1.4 3.6 3.6 4.2 7.6 1.6
2 8.1 o2 o2 o2 o2 o2 o2 1.6 2.8 3.7 4.0 5.2 2.1
3 59.2 o2 o2 o2 o2 o2 o2 3.9 7.0 9.3 9.9 12.9 5.3
4 10.3 o2 o2 o2 o2 o2 o2 1.7 3.3 5.2 5.9 3.2 0.2
5 40.7 o2 o2 o2 o2 o2 o2 1.9 8.7 14.3 16.4 4.5 2.0
6 8.1 o2 o2 o2 o2 o2 o2 1.2 4.5 4.5 5.7 6.1 0.4
BB, Bandrowski’s base; PPD, p-phenylenediamine.
1PPD- and BB-specific stimulation of lymphocytes from allergic patients. Patients 1–3 were described previously (Coulter et al., 2008). Current data are
derived from an additional blood donation obtained 12 months later (Coulter et al., 2008).
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CCL26) and IL17F was observed following stimulation of
allergic, but not tolerant, patient PBMCs.
Network-based analysis of allergic and tolerant patients’ gene
expression profiles
Ingenuity Pathway Assist was used to organize the differen-
tially expressed genes into networks of interacting genes
and to find modules of functionally related genes that
correspond to known pathways. In our analysis, the top-
scoring network (containing a maximum of 35 genes) from
antigen-stimulated allergic and tolerant individuals’ PBMCs
was considered. Genes associated with PPD-stimulated
allergic patients’ PBMCs were related to the immune
response, cellular growth, and proliferation. Several impor-
tant proinflammatory cytokine and chemokine genes were
upregulated, such as IL-17, CCL17, and CCL26, and these
proinflammatory genes included a subnetwork of known
relevance to Th2 responses (Figure 4a). Genes associated
with allergic patients’ PBMCs treated with BB formed a
profile similar to that of those treated with PPD (Figure 4b).
Several important proinflammatory and Th2-associated genes
were upregulated.
The top function associated with BB stimulation of tolerant
patients’ PBMCs was associated with immune response
(Figure 4d); however, within this network, the expression of
several proinflammatory genes was reduced, whereas the
expression of immunoregulatory genes such as IL-10 was
increased. Similarly, there was a downregulation of signaling
components, such as IFNAR2 (involved in STAT1 and 2
signaling), CXXC5 (involved in activating NF-kB and MAPK
signaling pathways), and CABLES1 (cyclin-dependent kinase
(CDK)-binding protein that has a role in proliferation and/or
differentiation), which could be attributed to the lack of
clinical symptoms in tolerant individuals. Genes from
tolerant individuals’ cells treated with PPD, although
associated with the immune response, were also different
from those seen in allergic patients (Figure 4c). Importantly,
there was no evidence of increased expression of the
cytokine genes associated with the development of a Th2
response.
Comparison of IL-5 and IL-13 gene expression and secretion
from PPD- and BB-stimulated allergic and tolerant patients’
PBMCs
Antigen-stimulated tolerant patients’ samples secreted lower
levels of IL-5 and IL-13, when allergic and tolerant patients
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0
–0.10
–0.20
–0.30
–0.40
–0.50
–0.60
Allergic patients
Tolerant patients
BB stimulation PPD stimulation
BB stimulation
PC component 1
(18.7% variance)
PC
 c
om
po
ne
nt
 2
(12
.5%
 va
ria
nc
e)
Allergic
Tolerant
PPD stimulation
Positive regulation of proliferation
Inflammatory response
Apoptosis
Humoral immune response
Lymphocyte activation
Inflammatory response
Positive regulation of proliferation
Apoptosis
Cellular protein metabolism
Chemotaxis
Cell growth
Humoral immune response
GPCR protein signaling pathway
Lymphocyte activation
Inflammatory response
Chemotaxis
Negative regulation of proliferation
Apoptosis
Regulation of programed cell death
Regulation of progression through cell cycle
GPCR protein signaling pathway
GPCR protein signaling pathway
–0.50–0.40–0.30–0.20–0.10 0 0.10 0.20 0.30 0.40 0.50 0
Figure 2. Gene changes associated with antigen stimulation of allergic and
tolerant patients’ lymphocytes. (a) Principal component analysis to detect
global variation between samples from allergic and tolerant patients. (b) Gene
lists common across allergic patients’ samples with respect to treatment,
generated and analyzed using FatiGOPlus software focusing on the
identification of key gene ontology biological processes.
P
<0.02
P
<0.02
P
<0.06
NS
P
<0
.05
P
<0
.02
P
<0
.03
NS
MIP-1α
2,000
Cytokine secretion (pg ml–1)
2001000 2001000
P
<0.002
NS
P
<0
.01NS
IL-4
IL-13
IL-5
1,0000
PP
D
BB
PP
D
BB
Al
le
rg
ic
To
le
ra
nt
Al
le
rg
ic
To
le
ra
nt
PP
D
BB
PP
D
BB
1,5001,0005000
P
<0.004
P
<0.004
P
<0.02NS
Figure 1. Cytokine secretion from p-phenylenediamine and Bandrowski’s
base stimulated lymphocytes. IL-4, IL-5, IL-13, and MIP-1a secretion
averaged from allergic and tolerant patients’ peripheral blood mononuclear
cells (PBMCs) in response to maximal stimulatory concentrations of p-
phenylenediamine and Bandrowski’s base.Data are presented as mean±SD,
with values from unstimulated PBMCs (less than 10 ngml1 (50 ngml1 for IL-
13)) subtracted.
164 Journal of Investigative Dermatology (2010), Volume 130
EM Coulter et al.
p-Phenylenediamine Allergy
were compared (Figure 1). Lower levels of cytokine secretion
were associated with decreased cytokine gene transcription
(Figure 5). Real-time-PCR analysis performed using fresh
samples from allergic patients and tolerant individuals,
24 hours after PPD or BB stimulation, confirmed the
microarray data.
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Figure 3. Genes of interest (Gene Ontology: Biological Process—Level 6) from allergic and tolerant patients’ lymphocytes that showed increased expression
in response to treatment with maximal stimulatory concentrations of p-phenylenediamine or Bandrowski’s base.
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Figure 4. Network representation of interactions between differentially expressed genes from the analysis of antigen-treated lymphocytes from allergic and
tolerant individuals. Genes colored gray represent the regulated genes’ input into the network; unshaded genes represent genes in the system database
associated with relevant networks. Circles highlight regulated T helper type 2 cytokine genes. (a) Allergic patients: PPD stimulation; (b) allergic patients: BB
stimulation; (c) tolerant patients: PPD stimulation; (d) tolerant patients: BB stimulation.
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Purified CD4þ and CD8þ T-lymphocyte proliferation with
PPD and BB
To define the CD phenotype of antigen-stimulated T cells from
allergic patients and tolerant individuals, purified CD4þ and
CD8þ T cells were cultured with autologous, irradiated
monocyte-derived dendritic cells and with either PPD or BB.
CD4þ and CD8þ T cells from allergic patients were stimulated
to proliferate by both PPD and BB (Figure 6a). In contrast, specific
proliferation of tolerant individuals’ cells was detected only for
purified CD4þ T cells and only in the presence of BB (Figure 6a).
Comparison of IL-5 and IL-13 secretion from PPD- and
BB-stimulated allergic and tolerant patients’ CD4þ and
CD8þ T-lymphocytes
High levels of IL-5 and IL-13, but not IFN-g, were detected
in supernatants from PPD- and BB-stimulated CD4þ
and CD8þ T cells from allergic patients. IL-5 and
IL-13 were also secreted from BB-stimulated tolerant
individuals’ CD4þ T cells, but at levels 80% lower than
those seen in equivalent samples from allergic patients
(Figure 6b).
Comparison of PBMC proliferation and cytokine secretion in an
independent cohort of 10 allergic patients and tolerant individuals
Using a new and expanded patient cohort (n¼10 allergic
patients and tolerant individuals), PBMC proliferation and
cytokine secretion were measured to determine whether Th2
cytokine secretion is a potential biomarker for discriminating
between PPD allergic patients and tolerant individuals. In
agreement with our previous findings, blood mononuclear
cells from allergic patients and tolerant volunteers prolifer-
ated with BB, but only allergic patients’ cells responded to
PPD (Figure 7). Significantly higher levels of IL-5 (Po0.01,
PPD; Po0.05, BB) and IL-13 (Po0.01, PPD; Po0.01, BB)
were secreted from allergic patients’ blood mononuclear
cells after antigen stimulation, when allergic and tolerant
individuals’ cells were compared (Figure 7). In agreement
with the original cohort, differences in the levels of IL-1a and
IL-6 were not detected on comparison of allergic and tolerant
individuals.
Because the expression of the IL-9 gene was upregulated
in allergic patients’ PBMCs stimulated with PPD and BB in
the microarray study, IL-9 secretion from allergic and tolerant
individuals’ PBMCs was measured in the expanded patient
cohort. IL-9 secretion was detected from allergic patients’
PBMCs stimulated with PPD and BB and from BB-stimulated
tolerant individuals’ PBMCs (Figure 7).
DISCUSSION
p-Phenylenediamine is one of the most common chemical
allergens associated with the development of contact
dermatitis (Schnuch et al., 1997), a prototype hypersensitivity
reaction with an asymptomatic sensitization phase, an
effector, and a resolution phase (Grabbe and Schwarz,
1998). Antigen-specific T cells are believed to be involved
in the pathogenesis; however, the reason that certain
individuals are particularly susceptible to PPD sensitization
remains largely unexplored.
We recently established the presence of antigen-specific
T cells in the circulation of allergic and most nonallergic
individuals (with or without previous hair dye exposure,
referred to herein as tolerant individuals (Coulter et al.,
2008)). PBMCs from both patient groups were stimulated
with BB; their presence seems to reflect an acquired immune
response that is not translated into an allergic reaction. This
theory is supported by human studies with cord blood, which
is not stimulated by BB (Coulter et al., 2008), and mouse
studies in which BB-specific T-cell responses were detectable
only after in vivo exposure (Farrell et al., 2009). In addition,
PBMCs from allergic patients were specifically stimulated
with PPD, which represents an important laboratory-based
discrimination between allergic and tolerant patient groups.
This difference between allergic and tolerant patients’ PBMCs
was reproduced in this study (Table 1).
The key objective of this study was to characterize the
functionality of antigen-specific PBMCs and purified CD4þ
and CD8þ T cells, focusing on whether the nature of the
induced cytokine secretion profile differs between allergic
and tolerant patient groups and whether such a difference
might be related to the development of contact dermatitis.
Supernatant taken from control and maximal stimulatory
concentrations of PPD and BB was collected from each
participant for the analysis of cytokine secretion. PPD and BB
stimulation of allergic patients’ PBMCs was associated with
the secretion of similar cytokines and chemokines (Table 2).
Of particular importance was the detection of the Th2
cytokines IL-4, IL-5, and IL-13, as well as IFN-g and TNF-a.
These findings are consistent with previous studies using
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Figure 5. Changes in cytokine gene expression levels using microarray
and real-time PCR analysis. Peripheral blood mononuclear cells from allergic
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concentrations of p-phenylenediamine and Bandrowski’s base for 24 hours.
Data are presented as mean±SD.
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T-cell clones from PPD-allergic patients (Sieben et al., 2002;
Coulter et al., 2008) as well as with the detection of high
levels of Th2 cytokines in skin from PPD-challenged mice
(Yokozeki et al., 2003) and the recently described association
between TNFA-308 G/A polymorphism and sensitization to
PPD (Blomeke et al., 2009). The cytokines IL-1 and IL-6 were
also detected in the supernatant of antigen-stimulated PBMC
cultures. IL-1 has been detected in individuals with psoriatic
keratinocytes and in chronically inflamed skin and shown to
be related to a general cutaneous alarm that triggers the
release of chemokines such as MIP-3a and IL-8 (Spiekstra
et al., 2005). IL-6 is produced by a variety of cells, including
keratinocytes, dendritic cells, and T cells, and is known as the
principal endogenous circulating pyrogen. Correia et al.
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(2002) recently detected high IL-6 levels in the blister fluid
and serum of patients with drug-induced toxic epidermal
necrolysis.
A comparison of cytokine secretion profiles from allergic
and tolerant patients’ PBMCs reveals several important
features. First, tolerant patients’ PBMCs incubated with BB,
which stimulates a proliferative response, secreted signifi-
cantly lower levels of the Th2 cytokines IL-4, IL-5, and IL-13
(4.3, 14.5, and 14.8%, respectively, that seen with
BB-stimulated PBMCs from allergic patients) and the chemo-
kine MIP-1a. Second, a trend toward higher levels of IL-8 and
IL-10 secretion was detected with tolerant patients’ PBMCs.
Third, PPD treatment of PBMCs from tolerant individuals,
which is not associated with a proliferative response,
stimulated secretion of the chemotactic protein IL-8 and
MCP-1, providing preliminary evidence that tolerant patients’
PBMCs respond to PPD, but in a manner different from that
with allergic patients.
It is possible that these antigen-driven differences between
patient groups may be a function of the individual (for
example, decreased Th2 cytokine secretion per se in tolerant
patients’ PBMCs) and not directly attributable to the chemical
interaction with cells from allergic and tolerant patients.
This explanation is difficult to accept, however, because
allergic and tolerant patients’ PBMCs secreted similar levels
of most cytokines/chemokines following PPD and BB
stimulation (Table 2), and stimulation with the protein
antigen tetanus toxoid was associated with IL-4, IL-5, and
IL-13 secretion in both patient groups (results not shown). It is
also possible that decreased cytokine secretion in PBMCs
from BB-treated volunteers might be an indication that only
one T-cell population is responding and that perhaps certain
Th2-producing T cells are missing. To address this question,
purified CD4þ and CD8þ T cells from allergic patients and
tolerant individuals were stimulated with PPD and BB, and
proliferation and cytokine secretion were assessed. CD4þ
and CD8þ T cells from allergic patients proliferated and
secreted high levels of the cytokines IL-5 and IL-13 after PPD
and BB stimulation. In contrast, in tolerant individuals,
proliferation and low levels of cytokine secretion were
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detected only in the CD4þ T-cell population. The detection
of antigen-specific, cytokine-secreting CD8þ T cells from
allergic patients alone provides an explanation for our
observed results with PBMCs and supports the hypothesis
that CD8þ T cells are important effectors in contact allergic
dermatitis (Vocanson et al., 2006, 2008). Somewhat surpris-
ingly, the upregulation of cytotoxic molecules such as
perforin, which are secreted from antigen-specific CD8þ
Tcells and thought to be involved in the pathogenesis of
allergic contact dermatitis in the mouse (Kehren et al., 1999),
was not detected in our study. In future experiments, we aim
to characterize the functionality of PPD-specific polyclonal
and monoclonal T cells from allergic patients, focusing
specifically on their ability to kill autologous target cells and
mechanisms of cytotoxicity. Finally, antigen concentration
and/or length of antigen exposure might have an effect on
T-cell cytokine production—the current study utilized max-
imal stimulatory antigen concentrations and one time point
for the analysis.To address this issue, a detailed kinetic study
using titrated antigen concentrations is in progress.
To explore whether differences in cytokine secretion from
PPD- and BB-stimulated allergic and tolerant individuals are
related to altered gene transcription, patients were recalled
and PBMC proliferation was assessed, together with an
analysis of gene expression using two methodologies:
microarray and real-time PCR. High levels of IL-5 and IL-13
cytokine secretion from antigen-stimulated samples from
allergic patients were associated with increased cytokine
gene expression (Figure 5). In contrast, tolerant patients’
PBMCs expressed low levels of Th2 cytokine genes after
stimulation. These data support previous studies in humans
and experimental animals indicating that PPD-specific T cells
preferentially secrete Th2 cytokines (Sieben et al., 2002;
Yokozeki et al., 2003; Coulter et al., 2008) and suggest that
the ability to produce a polarized Th2 response after antigen
stimulation may relate to susceptibility to the development of
contact dermatitis. A similar phenomenon has been observed
after intranasal or cutaneous exposure to the strong respira-
tory sensitizer trimellitic anhydride and in atopic dermatitis.
Sensitization to trimellitic anhydride is associated with IgE
antibody production driven by antigen-specific T-cell activa-
tion and secretion of IL-4, IL-5, and IL-13 (Grammer et al.,
2000; Dearman et al., 2002; Farraj et al., 2006). In atopic
dermatitis, a T-cell-mediated skin disease associated with IgE
production following exposure to environmental protein
antigens, the picture is more complex. In humans, some
CD4þ and CD8þ T cells have been found to secrete Th2
cytokines, which induce IgE production, and play a role in
the development of tissue destruction (Akdis et al., 2000,
2002, 2003; Teraki et al., 2000). We have recently shown
that PPD binds preferentially to serum protein in culture
(Coulter et al., 2008), generating a T-cell-stimulatory
hapten–protein complex (unpublished data). Interestingly,
using a panel of directly reactive chemical allergens
(excluding PPD), extracellular (serum) adduct formation was
found to be associated with the production of Th2 cytokines
in a mouse model (Hopkins et al., 2005). Therefore, it is
possible that the cellular pathophysiology of PPD-mediated
contact dermatitis and atopic dermatitis relates to the nature
of the antigenic determinant formed and the manner in which
it is handled by immune cells. Future studies should be aimed
at delineating the specific role of Th2-secreting CD4þ and
CD8þ T cells (and possibly IgE antibodies) in PPD-mediated
allergic contact dermatitis and the point in time at which they
begin to act as mediators in the immunopathology of the
disease.
The factors underlying antigen-driven differences in
cytokine secretion between allergic and tolerant patients
are unknown. Thus, microarray analysis was used to relate
cellular function to the expression levels of families of related
genes, with an overall aim of improving our understanding of
the cellular mechanisms of allergic contact dermatitis.
Differences between samples from allergic and tolerant
patients were immediately apparent when principal compo-
nent analysis was applied to the microarray data. It was
possible to separate data points on the basis of subject group
(Figure 2a), irrespective of the nature of antigen stimulation
(negative control, PPD, BB, or tetanus toxoid).
Although many biological processes associated with
antigen stimulation of allergic and tolerant patients’ samples
were similar (Figure 2b), regulated genes relating positive
regulation of cell proliferation and the humoral immune
response were absent in tolerant individuals. These data
suggest that differential gene regulation might explain why
only certain individuals develop clinical manifestations of
contact dermatitis despite the presence of antigen-specific
immunity in both patient groups. This hypothesis is supported
by the construction of functionally interlinking network
diagrams using the Ingenuity Pathway Assist (Mountain View,
CA) software program. Gene patterns associated with the
development of a Th2 cellular immune response were
evident in allergic patients’ samples, but absent in those
from tolerant individuals (Figure 4). Networks deriving from
allergic patients’ samples also contained the cytokine IL-9, a
signaling molecule secreted from memory T cells (Kajiyama
et al., 2007) that promotes IgE production by B cells and has
been implicated in allergic diseases such as asthma and food
allergy (Ying et al., 2002; Forbes et al., 2008). Recently, IL-9-
producing T cells were found to be a distinct T-cell
population, provisionally termed Th9 cells, deriving from
Th2 cells following programming in the presence of TGF-b
(Veldhoen et al., 2008). IL-9 secretion from PPD-stimulated
PBMCs was measured in the validation patient cohort (see
below). Several individual genes were also identified as being
unique among allergic individuals, including the Th2
cytokines discussed above; CCL17 and CCL26, which are
known to be associated with Th2-type T-cell recruitment
(Garcia et al., 2005); and IL-17F and IL-17 receptor B
(although stimulated PBMCs did not secrete IL-17) (Figure 4).
Genes regulated in the top-scoring network from tolerant
individuals treated with PPD and BB, although associated
with immunological functions, displayed a much more
regulatory profile involving TGF-b and IL-10 (Figure 4). Both
TGF-b and IL-10 are known to have anti-inflammatory
properties and are involved in the regulation of allergic
rhinitis and allergic reactions in the skin (Cavani et al., 1998;
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Benson et al., 2006). A network approach to analyzing
microarray data has previously been used to define late-phase
allergic reactions of the skin (Benson et al., 2006).
An independent, expanded cohort of allergic patients and
tolerant individuals (n¼ 10 per group) was recruited to
validate the major findings reported herein, namely, the
nature of the antigen stimulating a T-cell response (PPD and
BB with allergic patients’ PBMCs, BB with tolerant indivi-
duals’ PBMCs) and the lower levels of Th2 cytokines secreted
from tolerant individuals’ PBMCs (Figure 7). The validation
study also permitted an analysis of IL-9 secretion by PBMCs
stimulated with PPD and BB. IL-9 secretion was detected
from allergic patients’ PBMCs stimulated with PPD and BB
(Figure 7) and tolerant individuals’ PBMCs stimulated with
BB, at low levels. Further experiments are planned to define
the source of IL-9 secretion and the interplay between IL-9
and classic TH2-secreting cells in patients with allergic
contact dermatitis.
In conclusion, these data reveal several important func-
tional differences between PPD-stimulated PBMCs from
allergic and tolerant patients. In particular, PPD and BB
treatment of allergic patients’ samples was associated with
(i) the stimulation of CD4þ and CD8þ T cells and
(ii) significantly higher levels of Th2 cytokine secretion and
increased gene expression, which suggests that the ability to
produce cytokines such as IL-4, IL-5, IL-9, and IL-13
following antigen stimulation may be an important factor in
the development of contact dermatitis. Because the results
were validated in an independent patient cohort, the degree
of Th2 cytokine secretion seems to be a potential biomarker for
discriminating between individuals who are allergic to PPD
and those who are tolerant. The question of whether a Th2
cytokine secretion profile is peculiar to PPD or is prevalent in
most contact allergic reactions requires further investigation.
MATERIALS AND METHODS
Donor characteristics
Peripheral blood mononuclear cells (PBMCs) were isolated from
PPD-allergic, patch test–positive patients (n¼ 5 in patient cohort 1,
n¼ 10 in patient cohort 2) and hair dye–exposed volunteers (n¼ 6 in
volunteer cohort 1, n¼ 10 in volunteer cohort 2, from this point
referred to as PPD-tolerant (Table 3 and Figure 7). Approval for the
study was obtained from the local Liverpool research ethics
committee, and informed consent was obtained from all partici-
pants. Experiments were conducted in accordance with the
Declaration of Helsinki Principles.
Determination of PBMC proliferation
Proliferation of PBMCs from allergic and tolerant individuals was
measured using the lymphocyte transformation test, as described
previously (Naisbitt et al., 2003). PBMCs were cultured with PPD
and BB (final concentrations ranged from 0.1 to 20 mM), and absence
of the two chemicals was used as a negative control.
Measurement of PBMC cytokine/chemokine secretion
Supernatants (100ml) were collected from the lymphocyte transfor-
mation test, before the addition of [3H]thymidine, for the analysis of
cytokine/chemokine secretion, using a LINCOplex multiplex assay
kit (LINCO Research, Hampshire, UK). Protein (IL-1a, IL-1b, IL-4,
IL-5, IL-6, TGF-a, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, IFN-g, TNF-
a, eotaxin (CCL11), MCP-1 (CCL2), sCD40L, MIP-1a (CCL3), MIP-1b
(CCL4), IP-10 (CXCL10), and RANTES (CCL5)) content was measured
Table 3. Clinical details of allergic and tolerant patients
LTT (SI)
Age Sex1 Previous hair dye use PPD allergy Other allergy Months since reaction Patch test result PPD BB
Allergic patients
1 53 M Yes Yes Red, orange, and blue dye,
potassium dichromate
39 ++ 52.0 111.5
2 42 F Yes Yes 43 ++ 55.1 66.1
3 66 F Yes Yes Nickel, orange dye 87 ++ 8.6 21.6
4 46 F Yes Yes 37 ++ 74.1 20.4
5 67 F Yes Yes Unknown ++ 15.1 29.5
Tolerant patients
1 25 F Yes (M)2 No Np3 o2 7.6
2 49 F Yes (M) No Np o2 5.2
3 27 F Yes (M) No Np o2 12.9
4 35 M Yes (M) No Np o2 5.9
5 24 M No No Np o2 24.5
6 35 M Yes (M) No Np o2 6.1
1M, male; F, female.
2M, multiple hair dye exposures.
3Np, not performed because of ethical restrictions.
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using a Liquichip 100 workstation (Qiagen, West Sussex, UK) with
LiquiChip IS 2.3 software.
Microarray analysis
Peripheral blood mononuclear cells (PBMCs) (5 106) were cultured
with stimulatory concentrations of PPD and BB, as well as with a
DMSO (0.1% v/v) control. After 24 hours, cells were washed and
total RNA was isolated using Trizol reagent. The quality of RNA was
assessed by electrophoretic separation on an RNA Nano lab chip in
a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA); total RNA
samples with a 28S/18S band ratio greater than 1.6 were used for
target labeling. CodeLink human whole-genome arrays (http://
www.appliedmicroarrays.com) were scanned for the expression of
approximately 53,485 genes using a GenePix 4000B Array Scanner
(Molecular Devices, Sunnyvale, CA), optimized for laser scanning at
a wavelength of 635 nm. A detailed description of the methods used
and the quality control criteria fulfilled is given in the Supplementary
Materials and Methods.
For analysis, the data were imported into GeneSpring 7.3 GX
software (Agilent Technologies). Stringent data reduction was
achieved using filters: controls were removed within the chip;
filtering was applied on probe type accepting only discovery genes;
and filters were applied to discovery genes on the basis of flags
present in at least 8 of 24 samples. Identification of differential genes
was subsequently carried out by filtering upon fold change, accepting
genes whose expression was altered by greater than twofold either up
or down in the treated sample compared with the corresponding
negative control sample. By constructing gene lists, it was possible to
determine potential differences and/or similarities between allergic
and tolerant individuals. Genes unique to PPD and BB treatment for
each individual were analyzed using FatiGOPlus (fast assignment and
transference of information; Al-Shahrour et al., 2005) software (http://
www.babelomics.org), with a focus on identifying key gene ontology
biological processes. In addition, the Ingenuity Pathway Assist
application was used to organize differentially expressed genes into
networks of interacting genes and to find modules of functionally
related genes that also corresponded to pathways.
All primary data from this work are available from the
ArrayExpress database (http://www.ebi.ac.uk/microarray-as/ae) under
accession number E-MEXP-1812.
IL-5 and IL-13 gene expression analysis
Real-time PCR primers and probes for IL-5, IL-13, and GAPDH were
purchased from Applied Biosystems (Foster City, CA). Quantitative
PCR was performed using Taqman probe assays in the Platinum
Quantitative PCR Supermix-UDG kit (Invitrogen, Paisley, UK, cat
no. 11730-017). IL-5 and IL-13 expression was measured using a
Bio-Rad icycler (Bio-Rad Laboratories, Hemel Hempstead,
Hertfordshire, UK) and programmed for amplification as follows:
501C for 2minutes hold, 951C for 2minutes hold, then 45 cycles of
951C for 15 seconds to denature and 60–651C for 30–45 seconds to
anneal. Averaged Ct values were normalized back to the averaged Ct
values of a control gene (GAPDH). Adjusted average Ct values were
used to calculate the average of the biological replicates, and DCt was
then calculated between the control and the treated groups. Relative
expression levels of the same gene between two samples were
determined according to DCt values; a DCt valueo1 was considered
to signify no change.
Determination of purified CD4þ and CD8þ T-cell proliferation
To measure the proliferation of purified CD4þ and CD8þ T cells
from allergic patients and tolerant volunteers, PBMCs were isolated
on a density gradient of Lymphoprep and separated into two
aliquots. To generate monocyte-derived dendritic cells as a source of
antigen-presenting cells in the proliferation assay, the first aliquot of
PBMCs was cultured in 24-well plates for 4 hours, followed by
repeated washing to remove nonadherent cells. Adherent cells were
then cultured in medium, supplemented with IL-4 (800U/ml) and
GM-CSF (800U/ml). Half of the medium was replaced with fresh
complete medium on days 1, 3, and 5, and immature dendritic cells
were ready for use on day 6. The second PBMC aliquot was frozen,
then thawed on day 6, and CD4þ and CD8þ T cells were
positively selected by incubating PBMCs with immunomagnetic
microbeads coated with anti-CD4þ or anti-CD8þ antibodies and
magnetic cell sorting (Miltenyi Biotec, Bisley, UK). The purity of the
sorted T cells was determined using flow cytometry (Coulter EPICS
XL-MCL flow cytometer; Beckman Coulter, Fullerton, CA) with
conjugated CD3þ , CD4þ , and CD8þ antibodies (BD Bios-
ciences, Oxford, UK).
To test the antigen specificity of the purified CD4þ and CD8þ
T cells, T cells (1 105; total volume, 0.2ml) were incubated with
autologous irradiated (60Gy) dendritic cells (0.2 105) and PPD or
BB (0.5–2mg/ml). After 5 days, [3H]thymidine was added and
proliferation was measured by scintillation counting.
Supernatant was collected and stored from antigen-stimulated
PBMCs and purified T-cell cultures before the addition of
[3H]thymidine for the analysis of IL-5, IL-13, and IFN-g secretion,
using the methods outlined above.
Statistical analysis
Increases in cytokine secretion and cytokine gene expression resulting
from treatment with the test chemicals, and evaluated using microarray
and real-time PCR, were compared between patient groups, as well as
between PPD and BB treatment parameters, using the Mann–Whitney
test for nonparametric/non-normally distributed data. To identify
global differences between allergic and tolerant individuals, principal
component analysis was applied to the microarray data. Such analysis
is able to identify patterns in data of high dimension and express them
in such a way as to highlight their similarities and differences. Principal
component analysis was applied randomly, with no preformed
opinions as to how the data should be split.
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